In the case of the pharmaceutical sector, the people in question include not just the owners and managers of pharmaceutical firms but also consumers of pharmaceuticals. [...] In the context of the pharmaceutical sector, the key question is the prices which consumers best source of greater returns. [...] It risks begging the question of how to encourage the creative activity which leads to the existence of the commodity in the first place. [...] They dispute the assumptions used to generate the $800-million figure, particu- another important issue larly the treatment of the cost of using retained earnings in the pharmaceutical sector; is whether the current, this leads into the question of the treatment of one type of what economists term oppor- patent-based system tunity costs (as distinct from those types which are easily observed on ac [...] With regard to the TPD process in particular, the main question has been the time it takes for a drug to receive approval for sale in Canada, and whether the process has become so slow as to delay unnecessarily the release of valuable drugs.
health politics economics economy entrepreneurship science and technology research drugs business intellectual property medicine pharmaceutical industry risk monopoly prescription drugs legislation, drug clinical trial drug discovery fees, pharmaceutical patents as topic pharmaceutical policy health treatment government health care generic drug medical drugs clinical trials food and drug administration patent laws and legislation pharmaceutical services insurance generic monopolist steam engine james watt watt